Novo Nordisk Securities Class Action Lawsuit Alert: Shareholders May Be Entitled to Compensation

Strategic Insights -

Novo Nordisk A/S, a multinational pharmaceutical company, has been sued in a class action lawsuit alleging that the company provided false and misleading statements to investors about its growth potential and market expansion. The lawsuit claims that the defendants understated the impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood of patients switching to Novo Nordisk's branded alternatives. As a result, investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025, may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

Key Takeaways:

  • The lawsuit targets Novo Nordisk A/S for allegedly providing false and misleading statements to investors about its growth potential and market expansion.
  • The class action lawsuit claims that the defendants understated the impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood of patients switching to Novo Nordisk's branded alternatives.
  • Investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025, may be entitled to compensation through a contingency fee arrangement.
  • The lead plaintiff deadline is September 30, 2025.
  • The Rosen Law Firm, a global investor rights law firm, is representing the investors in this case and advises that investors should select qualified counsel with a track record of success in leadership roles.
  • The firm has achieved significant successes in securities class actions, including the largest ever securities class action settlement against a Chinese company at the time.
  • The Rosen Law Firm has been ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017 and has recovered hundreds of millions of dollars for investors in recent years.

Statistics:

  • The class period for the lawsuit is between May 7, 2025, and July 28, 2025.
  • The lead plaintiff deadline is September 30, 2025.
  • The Rosen Law Firm has secured over $438 million for investors in 2019 alone.
  • The firm's founding partner, Laurence Rosen, was named by law360 as a Titan of Plaintiffs Bar in 2020.

Sources:

  • "Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the Class Period), of the important September 30, 2025 lead plaintiff deadline."
  • "To join the Novo Nordisk class action, go to https://rosenlegal.com/submit-form/?case_id=34168 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information."
  • "A class action lawsuit has already been filed."